Technology Day 2021: Pathways to the Future of Cancer Research
Join Matthew Vander Heiden, recently named director of MIT’s Koch Institute for Integrative Cancer Research, to hear his vision for the future of cancer research at the Institute. From his research addressing one of the fundamental puzzles of cancer biology, to his work as a practicing oncologist, Vander Heiden draws on diverse and complementary perspectives as he guides the Koch Institute into its second decade. With his sights set on the big questions in cancer, and an eye toward opportunities to apply MIT’s strengths in machine learning and computer science to cancer challenges, he sees several pathways for MIT to make key new advances in the fight against cancer. This presentation was part of Virtual Tech Reunions 2021, Technology Day on June 5, 2021.

Technology Day 2021: Pathways to the Future of Climate Change

Use These 5 Food Hacks To Heal The Body & STARVE CANCER I Dr. William Li

C3 Chats: Biliary Tract Cancer Genomics

Managing Risk Factors to Maintain Brain Health, March 2026

What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service

CAR T and Bispecific Antibody Therapies in Multiple Myeloma

Technology Day 2021: Pathways to the Future of Computing

KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease (2025)

Stephen Meyer, John Lennox, and James Tour: Three Scientists on the Origins of Everything

AI-Proof Your Career: From Disruption to Opportunity

Ex-jefe de Oncología: Por Qué España Tiene Tantos Casos de Cáncer (la respuesta, en tu plato)

Building a $1.9 Billion FinTech Empire | Interview with Scott Ganeles, his Playbook and Journey

The MOFspace Webinar Series - Dr. Mathilde Lepoitevin

AI has hacked the code of human civilization | Yuval Noah Harari

Billionaire's WARNING: I'm SELLING. The Crash Is Already Here!

A Coag Conversation: 100 Years of Von Willebrand Disease and Upcoming Advances – Part 2

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial

Cardinal & Gray Society Holiday Luncheon

What’s Next in Type 1 Diabetes? Screening, Research Breakthroughs, and the Future of Care

